Inclusion completed

ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group; EORTC protocol 1410-BTG/AbbVie protocol M14-483

Cancer type: Head and Neck cancer

Phase: II

Principal Investigator: Mäenpää Hanna

Country: FI

Keywords: Finland, Helsinki

Status: Inclusion completed

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02343406?term=2014-004438-24&rank=1